Перспективы применения радионуклидных лекарственных препаратов при лечении злокачественных новообразований в РФ
https://doi.org/10.24411/2588-0519-2018-10044
Аннотация
В статье рассматриваются перспективы таргетной радионуклидной терапии (ТРТ) как одного из быстро растущих направлений ядерной медицины. Представлены характеристики, особенности воздействия, преимущества и недостатки наиболее применяемых α- и β-излучателей: 223Ra, 213Bi, 225Ac, 211At, 89Sr, 90Y, 131I, 153Sm, 177Lu. Обсуждаются новые подходы, основанные на использовании α-излучающих изотопов в терапии кастрационно-резистентного рака предстательной железы с костными метастазами, острого миелоидного лейкоза, меланомы, нейроэндокринных опухолей, опухолей головного мозга. Подчёркивается значимость ТРТ в рутинной клинической практике и необходимость скорейшего развития данного направления в нашей стране.
Об авторах
С. К. Зырянов
ФГАОУ ВО «Российский университет дружбы народов», Москва
Россия
Россия
д.м.н., профессор, зав. кафедрой общей и клинической фармакологии
SPIN-код: 2725-9981
К. Э. Затолочина
ФГАОУ ВО «Российский университет дружбы народов», Москва
Россия
Россия
к.м.н., ассистент кафедры общей и клинической фармакологии
SPIN-код: 9251-524
Список литературы
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. (2014). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–386. DOI: 10.1002/ijc.29210. Epub 2014 Oct 9.
2. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol. 2017 Aug;209(2):277–288. DOI: 10.2214/AJR.17.18264. Epub 2017 May 2.
3. Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017 Jul;18(7):e414–e423. DOI: 10.1016/S1470-2045(17)30379-0.
4. Zukotynski K, Jadvar H, Capala J, Fahey F. Targeted radionuclide therapy: practical applications and future prospects. Biomark Cancer. 2016; 8(suppl):35–38.
5. Родионова А., Шубина Д. Атомный взрыд: чем объясняется плачев¬ное состояние российской ядерной медицины // Vademecum. 2018;3. [Rodionova A, SHubina D. Atomnyi vzryd: chem ob yasnyaetsya plachevnoe sostoyanie rossiiskoi yadernoi meditsiny / Vademecum. 2018;3. (In Russ.).] URL: https://vademec.ru/article/atomnyy_vzryd-_chem_obyasnyaetsya_plachevnoe_ sostoyanie_rossiyskoy_yadernoy_meditsiny/
6. Уйба В.В. Ядерная медицина - проект будущего. Федеральное медико- биологическое агентство. [Uiba VV. Yadernaya meditsina — proekt budushchego. Federal'noe mediko-biologicheskoe agentstvo. (In Russ.).] URL: http://ipheb.ru/netcat_files/userfiles/7_Uyba.pdf
7. Курашвили Ю. Стратегия развития радиофармацевтической про¬мышленности в РФ 2030. ГК Росатом. IV ежегодный международный форум по развитию фармацевтической отрасли в России. «ФармЭволюция». [Kurashvili Yu. Strategiya razvitiya radiofarmatsevticheskoi promyshlennosti v RF 2030. GK Rosatom. IV ezhegodnyi mezhdunarodnyi forum po razvitiyu farmatsevticheskoi otrasli v Rossii. "FarmEvolyutsiya". (In Russ).] URL: https:// events.vedomosti.ru/events/pharma18/materials
8. Руководство для врачей. / Под ред. А.Ф. Цыба, Ю.С. Мардынского. – М.: ООО «МК», 2010. – 552 с. [Rukovodstvo dlya vrachei. / Ed by AF Tsyba, YuS Mardynskogo. (In Russ.).]
9. Middendorp M, Grünwald F. Update on recent developments in the therapy of differentiated thyroid cancer. Semin Nucl Med. 2010 ;40 (2):145–152. Elsevier Inc.
10. Van Dodewaard-de Jong J, Oprea-Lager D, Hooft L, et al. Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review. Eur Urol. 2015. European Association of Urology.
11. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(1):62S– 6S.
12. Valkema R, Pauwels S, Kvols L, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147–156.
13. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32(2):133–140.
14. Koppe MJ, Postema EJ, Aarts F, et al. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24(4):539–567.
15. Ghobrial I, Witzig T. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin’s Lymphoma. Oncology (Williston Park). 2004;18(3):623–630.
16. Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin’s lymphoma: from the "magic bullets" to “radioactive magic bullets. Yale J Biol Med. 2011;84(4):391–407.
17. Volkert WA, Goeckleler WF, Ehrhardt GJ, et al. Therapeutic radionuclides: production and decay property considerations. J Nucl Med. 1991;32(1):174–185.
18. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008 Sep;38(5):358–366. DOI: 10.1053/j.semnuclmed.2008.05.002.
19. Marcu L, Bezak E. Biomedical Physics in Radiotherapy for Cancer Ed. Allen B. 2012. Springer-Verlag London.
20. Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy--an overview. Curr Radiopharm. 2013 Sep;6(3):152–180.
21. Marcua L, Bezak E, Allend BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Critical Reviews in Oncology / Hematology. 123 (2018): 7–20.
22. Buchegger F, Perillo-Adamer F, Dupertuis YM, et al. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging. 2006; 33(11):1352–1363.
23. Kassis AI. The amazing world of auger electrons. Int J Radiat Biol. 2004 Nov-Dec;80(11–12):789–803.
24. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}- particle therapy. J Nucl Med. 2005 Jan;46 Suppl 1:199S–204S.
25. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 2012 Jun;33(3):573–590. DOI: 10.1007/s13277-011-0286-y. Epub 2011 Dec 6.
26. FDA Approves Xofigo for Advanced Prostate Cancer [Internet]. 2013. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=203971.
27. Dekempeneera Y, Keyaertsa M, Krasniqia A, et al. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert opinion on biological therapy. 2016. Vol. 16, No. 8, 1035–1047. URL: http://dx.doi.org/10.1080/14712598.2016.1185412.
28. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1–14. DOI: 10.2147/CMAR.S25537. Epub 2013 Jan 8.
29. Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012;30(Suppl 5) Abstr 8.
30. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223. DOI: 10.1056/NEJMoa1213755. PMID: 23863050.
31. Parker C, Vogelzang NJ, Sartor O, et al. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. J Clin Oncol. 2015;33(suppl 7):abstr. 195. Proceedings of the Genitourinary Cancers Symposium.
32. Pais HL, Alho I, Vendrell Is, et al. Radionuclides in oncology clinical practice — review of the literature. Dalton Transactions. 2017;46:14475–14487. DOI: 10.1039/C7DT01929G
33. Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017 Jul;18(7):e414–e423. DOI: 10.1016/S1470-2045(17)30379-0.
34. Allend B, Marcua L, Bezak E. Targeted Alpha Therapy for Cancer. 2016 In book: Advances in Medical Physics, Edition: Volume 6, Publisher: Medical Physics Publishing, Editors: Devon J. Godfrey, Jacob Van Dyk, Shiva K. Das, Bruce H. Curran, and Anthony B. Wolbarst, pp. 177–202.
35. Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–1239.
36. Caron PC, Jurcic JC, Scott AM, et al. A phase 1B trial of humanized antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994 83:1760–1768.
37. Jurcic J, Divgi C, McDevitt M. Potential for myeloablation with yttrium- 90-Hu (anti-CD33) in myeloid leukemia. Proc. Am. Soc. Clin. Oncol. 2000;19(8):M195.
38. Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol. 1993;11(2):294–303.
39. Jurcic J, Rosenblat T, McDevitt M. Phase I Trial of the Targeted Alpha- Particle Nano-Generator Actinium-225(225Ac)-Lintuzumab (anti-CD33; HuM195) In Acute Myeloid Leukemia (AML). Blood. 2011;118:768.
40. Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2014:e126–31. DOI: https://doi.org/10.14694/EdBook_AM.2014. 34.e126.
41. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 2005 Dec;4(12):1318–1324.
42. Allen BJ, Singla AA, Rizvi SMA, et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy. 2011;3(9):1041–1050.
43. Allen BJ, Raja C, Rizvi S, et al. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol. 2007;52(13):L15–19.
44. Sathekge M, Knoesen O, Meckel M, et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):1099–100. URL: https://doi.org/10.1007/ s00259-017-3657–9.
45. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–1944.
46. Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpharadionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19. DOI: 10.1007/s00259-014-2857–9.
47. Kratochwil C, Bruchertseifer F, Giesel F, et al. Ac-225-DOTATOC – an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56(3):1232.
48. Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008 Jan;49(1):30-8. DOI: 10.2967/jnumed.107.046938.
49. Morgenstern A, Krolicki L, Kunikowska J, et al. Targeted alpha therapy of glioblastoma multiforme: first clinical experience with 213Bi-substance P. J Nucl Med. 2014;55(Suppl. 1):390.
50. Государственный реестр лекарственных средств. [Gosudarstvennyi reestr lekarstvennykh sredstv. (In Russ).] URL: http://grls.rosminzdrav.ru/ Default.aspx.
51. A Review On The Development of Targeted Alpha Therapy in the Treatment of Cancer: Everyday Urology-Oncology Insights: Volume 2, Issue 2 https://www.urotoday.com/journal/everyday-urology-oncology-insights/ articles/98187-a-review-on-the-development-of-targeted-alpha-therapy-in-the-treatment-of-cancer-focusing-on-the-first-and-only-fda-approved-targeted-alpha-therapy-radium-223-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-mcrpc.html.
52. Резолюция по итогам Совета экспертов по определению места радия-223 в терапии пациентов с метастатическим кастрационно-резистентным раком предстательной железы. // Онкология сегодня. 2017;5(24):2–3. [Rezolyutsiya po itogam Soveta ekspertov po opredeleniyu mesta radiya-223 v terapii patsientov s metastaticheskim kastratsionno-rezistentnym rakom predstatel'noi zhelezy. Onkologiya segodnya. 2017;5(24):2–3. (In Russ.).]
53. Матвеев В.Б., Маркова А.С. Радий-223 в лечении кастрационно- резистентного рака предстательной железы с метастазами в кости. // Онкоурология. 2017;3(13):3–10. [Matveev VB, Markova AS. Radium-223 in treatment of castration-resistant prostate cancer with skeletal metastases. Cancer urology. 2017; 3(13):3–10. (In Russ).] DOI: 10.17650/1726-9776-2017-13-3-140–147.
Рецензия
Для цитирования:
Зырянов С.К., Затолочина К.Э. Перспективы применения радионуклидных лекарственных препаратов при лечении злокачественных новообразований в РФ. Качественная Клиническая Практика. 2018;(2):51-57. https://doi.org/10.24411/2588-0519-2018-10044
For citation:
Zyryanov S.K., Zatolochina K.E. Perspective for use of the radionuclide drugs in the treatment of malignant tumors in Russiaw. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2018;(2):51-57. (In Russ.) https://doi.org/10.24411/2588-0519-2018-10044
Просмотров: 721
Послать статью по эл. почте 